Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders

MYOMO, INC.

2024-Q2 EPS reported -$0.13 revenue$11,275,156

Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.
Record 213 MyoPro authorizations/orders (+70% YoY); backlog 282 units (+58% YoY).
1,179 patients in pipeline (+22% YoY); 550 new candidates added in Q2 (+35% YoY).
Gross margin 70.8% (product GM up 1,030 bps to 70.8%); net loss $1.1M ($0.03 EPS).
Q3 revenue guidance $8.0-8.5M; FY2024 revenue target $28-30M; targeting Q4 operating cash flow breakeven.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.